What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-08-10 compared with 2023-05-15 · 29 added, 19 removed, 27 unchanged (64% of the section changed)

Other Information.

Effective as of May 15, 2023, David Chacko, M.D., currently the Company’s Chief Financial Officer has been promoted to the dual position of Chief Financial Officer and Chief Business Officer of the Company.

Effective as of May 15, 2023, Nicholas (Nik) Chetwyn, Ph.D., has been promoted to the position of Chief Operating Officer of the Company.

Chetwyn, age 53, joined the Company in March 2021 as Senior Vice President of Operations.

Chetwyn brings over 25 years of experience in drug development in the pharmaceutical industry.

Prior to joining the Company, since October 2018, Dr.

Chetwyn has been the co-founder and president of MindScienceConnection, Inc., a strategy and leadership development company that focused on partnering with biopharmaceutical companies to navigate the unique challenges of building and maintaining thriving research cultures while developing the scientific leaders and executives of the future.

Prior to MindScienceConnection, from June 2006 to October 2018, Dr.

Chetwyn was an executive at Genentech, Inc.

in Small Molecule Drug Discovery where he helped build the small molecule drug development organization, helped drive the significant expansion of technical and drug manufacturing capabilities, served on multiple governance committees, was a technical development team leader for a small molecule inhibitor of AKT, and represented Genentech on the board of directors for the Allotrope Foundation.

While at Genentech, Nik supported new drug application (NDA) filings for ERIVEDGE and COTELLIC.

Prior to Genentech, from February 2002 to April 2006, Dr.

Chetwyn was an Associate Director at Pfizer Inc.

(Global R&D) (NYSE:

PFE) and also served as a pharmaceutical sciences team leader (PSTL) for a small molecule oncology project.

Prior to Pfizer, Dr.

Chetwyn held roles of increasing responsibility at GSK plc (formerly known as GlaxoSmithKline plc) where he was involved in the development of multiple small-molecule oncology candidates, new technology development and supplemental new drug application (sNDA) filings for WELLBUTRIN.

Chetwyn earned a M.S.

in pharmaceutical chemistry from the University of Kansas and a B.Sc.

in chemical and pharmaceutical sciences from the University of Sunderland.

On July 19, 2023, the board of directors (the Board) established the position of Lead Independent Director and amended our Corporate Governance Guidelines to set forth the duties and responsibilities of the position.

The Lead Independent Director’s primary duties and responsibilities include presiding over all meetings of the Board at which the Chairman of the Board is not present, including any executive sessions of the independent directors;

calling separate meetings of the independent directors, if needed;

providing feedback on Board meeting schedules and agendas;

acting as the liaison between the independent directors and the Chief Executive Officer and Chairman of the Board;

providing the Chairman of the Board with feedback and counsel regarding the Chairman’s interactions with the Board;

providing the Chairman of the Board and management with feedback on the quality, quantity, and timeliness of information provided to the Board;

responding to stockholder questions that are directed to the Lead Independent Director or the independent directors as a group;

and such other functions and responsibilities as requested by the Board from time to time.

Bristol, Ph.D.

was selected unanimously by the independent directors of the Board to serve as the Company’s first Lead Independent Director, with an initial term that will expire at our 2025 Annual Meeting and Dr.

Bristol may be considered for re-appointment thereafter.

Bristol will continue to serve as a member of the Board’s compensation committee and nominating and governance committee.

This disclosure is not required pursuant to Item 5(a) of Form 10-Q.

On August 7, 2023, Bihua Chen notified us of her decision to resign from the Board, effective immediately.

Chen informed the Board that her resignation from the Board, which she joined in March 2021, was triggered by the compliance policies of the investment fund that Ms.

Chen founded, and serves as the portfolio manager, Cormorant Asset Management, and was not due to a disagreement on any matter related to our operations, policies or practices.

We greatly appreciate the contributions Ms.

Chen made during her tenure on the Board.

On August 7, 2023, we sent a notice of termination to The Regents of the University of California (the Regents) with respect to our exclusive license agreement with the Regents dated December 21, 2018 (the UCSF License Agreement).

The termination will be effective as of October 6, 2023.

The UCSF License Agreement provided for an exclusive worldwide license, under specified patent rights controlled by the Regents relating to specific covalent inhibitors of GTP- and GDP-bound RAS proteins that target a novel region on RAS called the “switch II groove”

As previously disclosed in June 2023, we have deprioritized targeting S-IIG as part of our ERAS-2/3 research program.

As a result of the termination, the exclusive license granted to us under the UCSF License Agreement shall terminate as of October 6, 2023.

Exhibit Description

5 unchanged sentences

Amended and Restated Stockholders Agreement, dated April 15, 2020, by and among the Registrant and certain of its stockholders

Amended and Restated Employment Letter Agreement, dated April 10, 2023, between Shannon R.

Morris, M.D., Ph.D.

and Erasca, Inc.

Certification of Chief Executive Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

12 unchanged sentences

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August 10, 2023

/s/ Jonathan E.

1 unchanged sentence

(Principal Executive Officer)

August 10, 2023

Chief Financial Officer

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information